DOI QR코드

DOI QR Code

Obesity and Risk of Bladder Cancer: A Meta-analysis of Cohort Studies

  • Qin, Qi (Department of General Surgery, Childrens Hospital, Zhejiang University School of Medicine) ;
  • Xu, Xin (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Wang, Xiao (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Zheng, Xiang-Yi (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine)
  • Published : 2013.05.30

Abstract

Objective: Previous epidemiologic studies demonstrated that obesity might associated with the risk of bladder cancer. However, many of the actual association findings remained conflicting. To better clarify and provide a comprehensive summary of the correlation between obesity and bladder cancer risk, we conducted a meta-analysis to summarize results of studies on the issue. Stratified analyses were also performed on potential variables and characteristics. Methods: Studies were identified by searching in PubMed and Wanfang databases, covering all the papers published from their inception to March 10, 2013. Summary relative risks (SRRs) with their corresponding 95% confidence intervals (CIs) were calculated by either random-effect or fixed-effect models. Results: A total of 11 cohort studies were included in our meta-analysis, which showed that obesity was associated with an increased risk for bladder cancer in all subjects (RR=1.10, 95% CI=1.06-1.16; p=0.215 for heterogeneity; $I^2$=24.0%). Among the 9 studies that controlled for cigarette smoking, the pooled RR was 1.09 (95% CI 1.01-1.17; p=0.131 for heterogeneity; $I^2$=35.9%). No significant publication bias was detected (p = 0.244 for Egger's regression asymmetry test). Conclusions: Our results support the conclusion that obesity is associated with the increased risk of bladder cancer. Further research is needed to generate a better understanding of the correlation and to provide more convincing evidence for clinical intervention in the prevention of bladder cancer.

Keywords

References

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  2. Chen HS, Su LT, Lin SZ, et al (2012). Increased risk of urinary tract calculi among patients with diabetes mellitus--a population-based cohort study. Urology, 79, 86-92. https://doi.org/10.1016/j.urology.2011.07.1431
  3. Chow WH, Lindblad P, Gridley G, et al (1997). Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst, 89, 1453-7. https://doi.org/10.1093/jnci/89.19.1453
  4. DerSimonian R, Laird N(1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Dunn SE, Kari FW, French J, et al (1997). Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res, 57, 4667-72.
  6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  7. Flegal KM, Graubard BI, Williamson DF, Gail MH (2005). Excess deaths associated with underweight, overweight, and obesity. JAMA, 293, 1861-7. https://doi.org/10.1001/jama.293.15.1861
  8. Funfstuck R, Nicolle LE, Hanefeld M, Naber KG (2012). Urinary tract infection in patients with diabetes mellitus. Clin Nephrol, 77, 40-8. https://doi.org/10.5414/CN107216
  9. Haggstrom C, Stocks T, Rapp K, et al (2011). Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer, 128, 1890-8. https://doi.org/10.1002/ijc.25521
  10. Jankovic S, Radosavljevic V (2007). Risk factors for bladder cancer. Tumori, 93, 4-12.
  11. Jee SH, Yun JE, Park EJ, et al (2008). Body mass index and cancer risk in Korean men and women. Int J Cancer, 123, 1892-6. https://doi.org/10.1002/ijc.23719
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Jones ME, Swerdlow AJ (1998). Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol, 148, 1012-7. https://doi.org/10.1093/oxfordjournals.aje.a009567
  14. Key TJ, Appleby PN, Reeves GK, Roddam AW(2010). Insulinlike growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol, 11, 530-42. https://doi.org/10.1016/S1470-2045(10)70095-4
  15. Koebnick C, Michaud D, Moore SC, et al (2008). Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev, 17, 1214-21. https://doi.org/10.1158/1055-9965.EPI-08-0026
  16. Larsson SC, Andersson SO, Johansson JE, Wolk A (2008). Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer, 44, 2655-60. https://doi.org/10.1016/j.ejca.2008.07.012
  17. Mantel N, Haenszel W(1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  18. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 25, 285-95. https://doi.org/10.1007/s00345-007-0168-5
  19. Rinaldi S, Cleveland R, Norat T, et al (2010). Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer, 126, 1702-15.
  20. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  21. Zhao H, Grossman HB, Spitz MR, et al (2003). Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol, 169, 714-7. https://doi.org/10.1016/S0022-5347(05)63999-7

Cited by

  1. The association between physical activity and bladder cancer: systematic review and meta-analysis vol.110, pp.7, 2014, https://doi.org/10.1038/bjc.2014.77
  2. Obesity and cancer: the role of vitamin D vol.14, pp.1, 2014, https://doi.org/10.1186/1471-2407-14-712
  3. Awareness of Risk Factors for Cancer among Omani adults- A Community Based Study vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5401
  4. Interleukin-12 and Interleukin-6 Gene Polymorphisms and Risk of Bladder Cancer in the Iranian Population vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7869
  5. Association between the Metabolic Syndrome and High Tumor Grade and Stage of Primary Urothelial Cell Carcinoma of the Bladder vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1447
  6. Difference in the Incidences of the Most Prevalent Urologic Cancers from 2003 to 2009 in Iran vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1459
  7. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review vol.22, pp.1, 2014, https://doi.org/10.1111/iju.12644
  8. Obesity and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of 15 Cohort Studies vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0119313
  9. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1769-9
  10. Expression of Aquaporin 1 in Bladder Uroepithelial Cell Carcinoma and its Relevance to Recurrence vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3973
  11. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses vol.31, pp.9, 2016, https://doi.org/10.1007/s10654-016-0138-6
  12. Prediagnosis Body Mass Index and Risk of Secondary Primary Cancer in Male Cancer Survivors: A Large Cohort Study vol.34, pp.34, 2016, https://doi.org/10.1200/JCO.2016.66.4920
  13. Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study vol.7, pp.1, 2016, https://doi.org/10.1007/s13300-016-0152-4
  14. Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival vol.27, pp.5, 2017, https://doi.org/10.1097/MOU.0000000000000425
  15. Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer vol.9, pp.10, 2017, https://doi.org/10.3390/nu9101076
  16. Review of refractory ceramic fiber (RCF) toxicity, epidemiology and occupational exposure vol.30, pp.2, 2018, https://doi.org/10.1080/08958378.2018.1448019
  17. Estimating the impact of body mass index on bladder cancer risk: Stratification by smoking status vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-19531-7
  18. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women pp.00207136, 2018, https://doi.org/10.1002/ijc.31597
  19. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer pp.1433-8726, 2018, https://doi.org/10.1007/s00345-018-2397-1
  20. Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause pp.1573-7225, 2019, https://doi.org/10.1007/s10552-019-1131-7
  21. Association of body mass index with bladder cancer risk in men depends on abdominal obesity pp.1433-8726, 2019, https://doi.org/10.1007/s00345-019-02690-1
  22. Prediagnosis obesity and secondary primary cancer risk in female cancer survivors: A national cohort study vol.8, pp.2, 2019, https://doi.org/10.1002/cam4.1959